Se‐Hoon Lee

32.6k total citations · 5 hit papers
617 papers, 17.4k citations indexed

About

Se‐Hoon Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Se‐Hoon Lee has authored 617 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 315 papers in Oncology, 286 papers in Pulmonary and Respiratory Medicine and 109 papers in Cancer Research. Recurrent topics in Se‐Hoon Lee's work include Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (114 papers) and Cancer Genomics and Diagnostics (82 papers). Se‐Hoon Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (114 papers) and Cancer Genomics and Diagnostics (82 papers). Se‐Hoon Lee collaborates with scholars based in South Korea, United States and Ethiopia. Se‐Hoon Lee's co-authors include Keunchil Park, Jin Seok Ahn, Dae Seog Heo, Myung‐Ju Ahn, Tae Min Kim, Jong‐Mu Sun, Bhumsuk Keam, Dong‐Wan Kim, Doo Hyun Chung and Yung‐Jue Bang and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Se‐Hoon Lee

586 papers receiving 17.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

2019 322 citations Jong‐Mu Sun, Jin Seok Ahn et al. profile →
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

2017 300 citations Se‐Hoon Lee et al. Journal of Clinical Oncology profile →
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features

2024 50 citations Se‐Hoon Lee et al. profile →
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer

2025 25 citations Se‐Hoon Lee et al. profile →

Peers

Countries citing papers authored by Se‐Hoon Lee

Since Specialization

Citations

This map shows the geographic impact of Se‐Hoon Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Se‐Hoon Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Se‐Hoon Lee more than expected).

Fields of papers citing papers by Se‐Hoon Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Se‐Hoon Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Se‐Hoon Lee. The network helps show where Se‐Hoon Lee may publish in the future.

Co-authorship network of co-authors of Se‐Hoon Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Se‐Hoon Lee. A scholar is included among the top collaborators of Se‐Hoon Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Se‐Hoon Lee. Se‐Hoon Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer 2024 ·Cancer Research ·Jesse Boumelha, (unknown), Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, (unknown), Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se‐Hoon Lee, Míriam Molina‐Arcas, Julian Downward	10
2	Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18 2024 ·JTO Clinical and Research Reports ·(unknown), (unknown), Young Saing Kim, Keon Uk Park, Jang Ho Cho, Hong-Sik Kim, Ki Hyeong Lee, (unknown), Il Hwan Kim, Kyung Hee Lee, Gyeong‐Won Lee, Seong Yoon Yi, Byeong‐Cheol Ahn, Min-Young Lee, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Jin Seok Ahn, Se‐Hoon Lee, Myung‐Ju Ahn	1
3	Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden 2024 ·eLife ·(unknown), (unknown), (unknown), Yeon Jeong Kim, Woong‐Yang Park, Se‐Hoon Lee, Murim Choi	5
4	99mTc-DMSA and 99mTc-DTPA identified renal dysfunction due to microplastic polyethylene in murine model 2024 ·Chemosphere ·Javeria Zaheer, (unknown), (unknown), (unknown), In Ok Ko, (unknown), (unknown), Se‐Hoon Lee, Jin Su Kim	3
5	Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM) 2024 ·Journal of Clinical Oncology ·Sehhoon Park, (unknown), Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yu Jung Kim, Youngjoo Lee, Dong‐Wan Kim, Sang‐We Kim, Ki Hyeong Lee, Won-Jae Lee, Jung Won Choi, Kyuha Chong, Jung-Il Lee, (unknown), Nak‐Hoon Son, Myung‐Ju Ahn	23
6	Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Marina Chiara Garassino, Heather A. Wakelee, Jonathan Spicer, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, (unknown), Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Jing Yang, Ashwini Arunachalam, Josephine M. Norquist, Steven M. Keller, Shugeng Gao	2
7	Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer 2024 ·JCO Precision Oncology ·Hyojin Kim, Seokhwi Kim, Sangjoon Choi, Changhee Park, Seonwook Park, Sérgio Pereira, Minuk Ma, Donggeun Yoo, Kyunghyun Paeng, (unknown), Sehhoon Park, Chan‐Young Ock, Se‐Hoon Lee, (unknown), Jin-Haeng Chung	12
8	Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). 2024 ·Journal of Clinical Oncology ·Maria E. Cabanillas, (unknown), Marcia S. Brose, Ray McDermott, (unknown), Jessica R. Bauman, Michela Casanova, Shivaani Kummar, Se‐Hoon Lee, Serge Leyvraz, Do‐Youn Oh, Lin Shen, (unknown), (unknown), Chiara Mussi, David S. Hong, Alexander Drilon, Steven G. Waguespack	4
9	A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma. 2024 ·Journal of Clinical Oncology ·Sehhoon Park, Hyun Ae Jung, Se‐Hoon Lee, Junhun Cho, Kyungmi Yang, Dongryul Oh, Yong Chan Ahn, Eun‐Hye Kim, Nayeon Choi, (unknown), Myung‐Ju Ahn	0
10	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	10
11	KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. 2023 ·Journal of Clinical Oncology ·Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Jie He, Shugeng Gao, Ke‐Neng Chen, (unknown), Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Steven M. Keller, Ayman Samkari, Jonathan Spicer	11
12	Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Cancer Research and Treatment ·Hana Kim, Sehhoon Park, Hyun Ae Jung, Se‐Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung‐Ju Ahn	14
13	Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer 2023 ·Cancer ·Sehhoon Park, Yu Jung Kim, Young Joo Min, Peter G. Mortimer, Heejung Kim, Simon A. Smith, Emma Dean, Hyun Ae Jung, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Se‐Hoon Lee, Keunchil Park	15
14	Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study 2022 ·SHILAP Revista de lepidopterología ·Bo Mi Ku, (unknown), Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yoon‐La Choi, Myung‐Ju Ahn	1
15	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors 2019 ·Clinical Cancer Research ·Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin	132
16	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC 2019 ·Journal of Thoracic Oncology ·Sehhoon Park, Hayoon Lee, Boram Lee, Se‐Hoon Lee, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	58
17	Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK -Rearranged NSCLC 2018 ·Clinical Cancer Research ·Ka‐Won Noh, Insuk Sohn, Ji‐Young Song, (unknown), Yu‐Jin Kim, Kyungsoo Jung, (unknown), Mingi Kim, (unknown), Joungho Han, Se‐Hoon Lee, Mi‐Sook Lee, Yoon‐La Choi	17
18	Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors 2016 ·Cancer Immunology Research ·Yaewon Yang, (unknown), Tae Min Kim, Yong‐Oon Ahn, Hana Choi, (unknown), Bokyung Min, Jung Hyun Her, (unknown), Bhumsuk Keam, Se‐Hoon Lee, Dong‐Wan Kim, Yu Kyeong Hwang, Dae Seog Heo	128
19	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer 2015 ·Clinical Cancer Research ·(unknown), Tae Min Kim, Dong‐Wan Kim, Soyeon Kim, Bhumsuk Keam, Se‐Hoon Lee, Dae Seog Heo	99
20	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 2015 ·Clinical Cancer Research ·Ji Yun Lee, Jong‐Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa‐Na Song, Bo Mi Ku, Jiae Koh, (unknown), Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact